Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 3
5(83.3%)
Phase 2
1(16.7%)
6Total
Phase 3(5)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05611931Phase 3Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Role: collaborator

NCT05581121Phase 3Recruiting

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Role: collaborator

NCT03555422Phase 3Completed

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

Role: collaborator

NCT07107477Phase 3Recruiting

TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden

Role: lead

NCT05201001Phase 2Withdrawn

APX005M in Patients With Recurrent Ovarian Cancer

Role: collaborator

NCT04989647Phase 3Recruiting

Intermediate Risk Cervical Cancer: Radical Surgery +/- Adjuvant Radiotherapy

Role: lead

All 6 trials loaded